CND Life Sciences, Inc.
Publicly observedScottsdale, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Scottsdale | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | CND Life Sciences, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | N8BNGXXEBP75 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant5 Sept 2025Publicly observed
NIH SBIR/STTR award: Analysis of Cutaneous Phosphorylated alpha-Synuclein to Identify Patients at Risk of Progressing from Essential Tremor to Parkinson's Disease
USD 1,012,800.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant5 Sept 2025Publicly observed
NIH SBIR/STTR award: Analysis of Cutaneous Phosphorylated alpha-Synuclein to Identify Patients at Risk of Progressing from Essential Tremor to Parkinson's Disease
USD 1,276,662.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.